CONSHOHOCKEN, PA — Tiger BioSciences has acquired Platelet-Rich Fibrin Matrix, or PRFM, technology from Bahia Medical Inc., adding a powerful new regenerative medicine platform to its growing wound-care portfolio and setting its sights on a commercial rollout next year.
The deal brings Tiger proprietary PRFM tubes and a novel wound-dressing system that allows clinicians to prepare and apply a patient’s own platelet-rich fibrin directly at the point of care. The approach is designed to accelerate healing in chronic and complex wounds by using concentrated growth factors and biological signals drawn from the patient’s own blood.
Unlike traditional platelet-rich plasma products, the PRFM system is built around a flexible, wearable dressing that can be applied across a wide range of wound sizes. The patch can absorb wound fluid and activate the PRFM in place, creating what Tiger describes as an autologous healing environment that works continuously at the injury site.
“With this acquisition, Tiger BioSciences is taking another significant step toward diversifying its portfolio and strengthening our commitment to autologous wound care therapies,” said Oliver Burckhardt, the company’s co-chief executive. He said the technology fits squarely with Tiger’s push to deliver first-to-market products that improve outcomes for patients with difficult-to-treat wounds.
The purchase also broadens Tiger’s reach in regenerative medicine, an area of healthcare drawing growing attention as providers look for ways to reduce complications, shorten healing times, and lower the overall cost of care. PRFM therapies are especially attractive because they rely on a patient’s own biology rather than donor tissue or synthetic drugs.
Garrett Grinsfelder, president of Tiger Wound Care, said the addition will give clinicians more intuitive and advanced tools in settings ranging from hospitals to outpatient clinics.
“This acquisition enhances our ability to support clinicians with tools that are advanced, intuitive, and designed to elevate the standard of care,” he said.
Tiger BioSciences said it will continue developing the PRFM and dressing technologies, complete clinical trials, and pursue 510(k) clearance from the Food and Drug Administration, with the goal of launching the products commercially in late 2026.
In a wound-care market hungry for innovation, the deal signals that Tiger intends to be more than a supplier of dressings. It wants to be a player in the next generation of biologically driven healing.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.